

# Pharmaceutical pricing and reimbursement policies in the in- and out-patient sector


Stefan Meli, Sylvana Magrin Sammut, Tanya Formosa  
Directorate for Pharmaceutical Affairs, Ministry for Health and Active Ageing, Malta  
Contact: stefan.meli@govl.mt




## FACTS & FIGURES

- Population (2022) 542, 051
- Country size (2024): 316 km<sup>2</sup>
- Healthcare sector: NHS, tax-funded
- GDP per capita (2022): € PPP 35,992
- Health expenditure (2022) per capita: €3,055
- Health expenditure in % of GDP: 10.7% (in 2020)
- Public health expenditure as % of total (in 2020): 67%
- Pharmaceutical expenditure & medical device expenditure per capita (2020): €825
- Pharmaceutical expenditure & medical device expenditure in % of HE: 27%
- Public pharmaceutical expenditure as % of total health expenditure: 14%

## PRICING



## REIMBURSEMENT



**Legal Notice 58 of 2009 criteria:**

- Registration status in Malta.
- Schedule V condition.
- Diagnostic and other requirements or costs for use of medicinal product.
- Value/extent/relevance of information & evidence available, particularly in terms of innovation, therapeutic effectiveness improvement, safety, efficacy, impact on availability & versatility, cost-effectiveness comparison to other available medicines and other treatment modalities.
- Cost and economic evaluation.

**Health Act (Cap. 528) of 2013 criteria:**

- International evidence
- HTAs
- Consultation with relevant stakeholders
- Capacity within the public health system
- Social and epidemiological considerations
- Affordability and sustainability